About: Fatal outcome of human coronavirus NL63 infection despite successful viral elimination by IFN‐alpha in a patient with newly diagnosed ALL

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Fatal outcome of human coronavirus NL63 infection despite successful viral elimination by IFN‐alpha in a patient with newly diagnosed ALL Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Fatal outcome of human coronavirus NL63 infection despite successful viral elimination by IFN‐alpha in a patient with newly diagnosed ALL
Creator	Mayer, Karin Drosten, Christian Brossart, Peter Wolf, Dominik Nellessen, Cordula Pietzonka, Sandra Schumacher, Martin Eis-H€ Ubinger, Anna Hahn-Ast, Corinna
Source	Medline; PMC
abstract	INTRODUCTION: Human coronavirus NL63 (HCoV‐NL63) is one of four common human respiratory coronaviruses. Despite high incidence, HCoV infections are grossly understudied. We here report a case of HCoV infection in a leukemia patient with fatal ARDS despite successful virus elimination by pegylated interferon‐alpha (PEG‐IFN‐α). CASE: The 27‐year‐old female pre‐T‐ALL patient was treated according to the German‐Multicenter Trial for Adult ALL protocol. No relevant infectious complications were seen until day 35 when the neutropenic patient developed fever without any clinical focus. Antibiotic prophylaxis was switched to meropenem. The patient deteriorated rapidly with respiratory failure due to ARDS. Anti‐infectious therapy was escalated to additional linezolid and liposomal amphotericine‐B. BAL revealed a significant viral load of HCoV‐NL63. Based on successful application of PEG‐IFN against the related SARS coronavirus in animal experiments, a single injection of 180 μg PEG‐IFN‐α2b was applied. Despite immediate initiation of treatment and elimination of virus in subsequent tests, the progressive lung failure led to death 7 d after onset of fever with massive lung bleeding as a consequence of diffuse alveolar hemorrhage. CONCLUSION: This report emphasizes the fatal consequences of common respiratory virus infections in immunocompromised patients. HCoV‐NL63 replication can be reduced by treatment with peg‐IFN if diagnosed early.
has issue date	2016-03-04(xsd:dateTime)
bibo:doi	10.1111/ejh.12744
bibo:pmid	26854965
has license	no-cc
sha1sum (hex)	d308bd286f894ad8168fa7501741c552e46cc697
schema:url	https://doi.org/10.1111/ejh.12744
resource representing a document's title	Fatal outcome of human coronavirus NL63 infection despite successful viral elimination by IFN‐alpha in a patient with newly diagnosed ALL
has PubMed Central identifier	PMC7163643
has PubMed identifier	26854965
schema:publication	Eur J Haematol
resource representing a document's body	covid:d308bd286f894ad8168fa7501741c552e46cc697#body_text
is schema:about of	named entity 'patient' named entity 'application' named entity 'replication' named entity 'respiratory' named entity 'emphasizes' named entity 'LEUKEMIA' named entity 'FATAL' named entity 'INFECTIOUS COMPLICATIONS' named entity 'MASSIVE' named entity 'RELATED' named entity 'DIFFUSE ALVEOLAR HEMORRHAGE' named entity 'ONSET OF' named entity 'SIGNIFICANT' named entity 'TREATMENT' named entity 'CONSEQUENCES' named entity 'PROTOCOL' named entity 'IFN-A' named entity 'SEEN' named entity 'CONCLUSION' named entity 'SUBSEQUENT' named entity 'SINGLE' named entity 'PATIENT' named entity 'A2B' named entity 'ANIMAL EXPERIMENTS' named entity 'REPLICATION' named entity 'NL63' named entity 'PROGRESSIVE' named entity 'INFECTION' covid:arg/d308bd286f894ad8168fa7501741c552e46cc697 named entity 'protocol' named entity 'Despite' named entity 'immunocompromised' named entity 'Conclusion' named entity 'understudied' named entity 'infections' named entity 'coronaviruses' named entity 'fatal' named entity 'consequence' named entity 'additional' named entity 'initiation' named entity 'IFN-a' named entity 'liposomal' named entity 'Human coronavirus NL63' named entity 'fever' named entity 'fever' named entity 'lung' named entity 'IFN' named entity 'respiratory failure' named entity 'IFN' named entity 'human coronavirus' named entity 'IFN-alpha' named entity 'infection' named entity 'Fatal outcome' named entity 'prophylaxis' named entity 'viral infection' named entity 'mechanical ventilation' named entity 'HCoV-NL63' named entity 'immune response' named entity 'immunocompromised' named entity 'coronavirus' named entity 'Human coronavirus NL63' named entity 'HCoV-NL63' named entity 'IFN-a' named entity 'secretion' named entity 'HCoV-NL63' named entity 'septic shock' named entity 'fever' named entity 'NL63' named entity 'Bronchoalveolar lavage' named entity 'immunosuppressive' named entity 'partial pressure of oxygen' named entity 'cotrimoxazole' named entity 'SARS-CoV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software